MYGN · Myriad Genetics Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MYGN

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$824.50M	$837.60M	$753.20M	$678.40M	$557.10M	$638.60M
Cost of Revenue	$247.90M	$252.20M	-	-	-	-
Gross Profit	$576.60M	$585.40M	$517.00M◇	$476.40M◇	-	-
R&D	$106.80M	$113.40M	$88.70M	$85.40M	$73.30M	$77.20M
SG&A	$256.80M	$275.90M	$572.90M	$514.70M	$496.90M	$510.10M
Total Operating Expenses	$963.80M	$708.90M	$1.01B	$819.00M	$846.80M	$870.30M
D&A	$53.70M	$61.20M	$61.90M	$52.70M	$62.80M	$72.00M
Operating Income	($387.20M)	($123.50M)	($257.40M)	($140.60M)	($289.70M)	($231.70M)
Interest Expense	$10.50M	$2.80M	$2.90M	$3.20M	$11.20M	$10.80M
Income Tax	($29.20M)	$3.80M	$1.10M	($28.60M)	($59.90M)	($23.70M)
Net Income	($365.90M)	($127.30M)	($263.30M)	($112.00M)	($223.60M)	($199.50M)
EPS - Basic	($3.95)	($1.41)	($3.18)	($1.39)	($2.99)	($2.69)
EPS - Diluted	($3.95)	($1.41)	($3.18)	($1.39)	($2.99)	($2.69)

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$149.60M	$102.40M	$132.10M	$56.90M	$258.40M	$117.00M
Accounts Receivable	$115.30M	$121.20M	$114.30M	$101.60M	$91.30M	$89.50M
Inventory	$30.60M	$27.50M	$22.00M	$20.10M	$15.30M	$27.10M
Accounts Payable	$30.00M	$32.30M	$25.80M	$28.80M	$29.60M	$20.50M
Current Assets	$332.60M	$298.00M	$313.60M	$274.60M	$484.80M	$389.40M
Total Assets	$706.60M	$1.03B	$1.15B	$1.20B	$1.32B	$1.42B
Current Liabilities	$133.80M	$164.10M	$155.90M	$137.20M	$204.30M	$145.90M
Long-term Debt	$119.90M	$39.60M	$38.50M	$0	$0	$224.40M
Total Liabilities	$338.60M	$326.50M	$363.30M	$312.90M	$352.90M	$537.80M
Stockholders' Equity	$368.00M	$701.10M	$783.20M	$885.80M	$967.80M	$881.00M
Retained Earnings	($1.12B)	($756.80M)	($629.50M)	($366.20M)	($254.20M)	($227.00M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$1.80M	($8.70M)	($110.90M)	($106.30M)	$18.20M	$60.70M
Investing Cash Flow	($27.40M)	($11.90M)	$31.90M	($77.50M)	$274.40M	$19.30M
Financing Cash Flow	$64.20M	($7.40M)	$152.90M	($8.00M)	($150.60M)	($10.00M)
CapEx	-	-	-	$45.30M	$18.00M	$10.20M
Free Cash Flow	-	-	-	($151.60M)	$200.0K	$50.50M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	69.9%	69.9%	68.6%	70.2%	-	-
Operating margin	-47.0%	-14.7%	-34.2%	-20.7%	-52.0%	-36.3%
EBITDA margin	-40.4%	-7.4%	-26.0%	-13.0%	-40.7%	-25.0%
Net margin	-44.4%	-15.2%	-35.0%	-16.5%	-40.1%	-31.2%
Free cash flow margin	-	-	-	-22.3%	0.0%	7.9%
FCF / Net income	-	-	-	1.35	-0.00	-0.25
R&D / Revenue	13.0%	13.5%	11.8%	12.6%	13.2%	12.1%
SG&A / Revenue	31.1%	32.9%	76.1%	75.9%	89.2%	79.9%
Effective tax rate	-	-	-	-	-	-
Return on assets	-51.8%	-12.4%	-23.0%	-9.3%	-16.9%	-14.1%
Return on equity	-99.4%	-18.2%	-33.6%	-12.6%	-23.1%	-22.6%
Return on invested capital	-62.7%	-13.2%	-24.7%	-12.5%	-23.6%	-16.6%
Liquidity
Current ratio	2.49	1.82	2.01	2.00	2.37	2.67
Quick ratio	2.26	1.65	1.87	1.85	2.30	2.48
Cash ratio	1.12	0.62	0.85	0.41	1.26	0.80
Leverage
Debt / Equity	0.33	0.06	0.05	0.00	0.00	0.25
Debt / Assets	0.17	0.04	0.03	0.00	0.00	0.16
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-36.9x	-44.1x	-88.8x	-43.9x	-25.9x	-21.5x
Equity multiplier	1.92	1.47	1.46	1.35	1.36	1.61
Liabilities / Assets	0.48	0.32	0.32	0.26	0.27	0.38
Efficiency
Asset turnover	1.17	0.82	0.66	0.57	0.42	0.45
Inventory turnover	8.10	9.17	-	-	-	-
Days sales outstanding	51d	53d	55d	55d	60d	51d
Days inventory outstanding	45d	40d	-	-	-	-
Days payable outstanding	44d	47d	-	-	-	-
Cash conversion cycle	52d	46d	-	-	-	-
Valuation
P / E	-	-	-	-	-	-
P / B	1.5x	1.8x	2.0x	1.3x	2.1x	1.7x
P / S	0.7x	1.5x	2.1x	1.7x	3.7x	2.3x
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	-1.6%	11.2%	11.0%	21.8%	-12.8%	-25.0%
Revenue CAGR (3y)	6.7%	14.6%	5.7%	-7.3%	-9.1%	-6.1%
Revenue CAGR (5y)	5.2%	-0.3%	0.3%	-2.5%	-5.9%	-2.5%
Gross profit growth (YoY)	-1.5%	13.2%	8.5%	-	-	-
Operating income growth (YoY)	-213.5%	52.0%	-83.1%	51.5%	-25.0%	-
Net income growth (YoY)	-187.4%	51.7%	-135.1%	49.9%	-12.1%	-
EPS growth (YoY)	-180.1%	55.7%	-128.8%	53.5%	-11.2%	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	-	-	-	-	-99.6%	-32.8%
FCF CAGR (5y)	-	-	-	-	-73.8%	-15.4%
Book value growth (YoY)	-47.5%	-10.5%	-11.6%	-8.5%	9.9%	-19.1%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Product / service

$824.50M total

Hereditary Cancer$372.40M · 45.2%

Prenatal$186.30M · 22.6%

Mental Health$144.10M · 17.5%

Tumor Profiling$121.70M · 14.8%

Geographic

$824.50M total

US$768.00M · 93.1%

Non Us$56.50M · 6.9%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-1.23

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✗Net income positive
✓Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✓Current ratio improved
✗No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: In Vitro & In Vivo Diagnostic Substances

Company	Revenue (last FY)	Net margin	ROE
VNRX	$1.73M	-1352.2%	68.2%
QDEL	$2.73B	-41.5%	-58.9%
LNTH	$1.54B	15.2%	21.4%
IDXX	$4.30B	24.6%	66.0%
NEOG	$894.66M	-122.1%	-52.7%

Comparing MYRIAD GENETICS INC against the 5 most active filers in the same SIC group.

Dividends

$0.00/share trailing 12 months

Ex-date	Per share
Jul 1, 2009	$1.7500
Jun 15, 2009	$1.7500

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.